about
Niacin as a drug repositioning candidate for hyperphosphatemia management in dialysis patientsAntiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim DatabaseAttitudes to proposed assessment of pharmacy skills in Korean pharmacist licensure examinationTherapeutic duplicate prescribing in Korean ambulatory care settings using the National Health Insurance claim data.Impact of statins on risk of new onset diabetes mellitus: a population-based cohort study using the Korean National Health Insurance claims database.Discovery of an orally available PAR-1 antagonist as a novel antiplatelet agent.Physicians' and pharmacists' acceptance of online, real-time "drug combinations to avoid" messages.Potentially inappropriate medication use at ambulatory care visits by elderly patients covered by National Health Insurance in Korea.Impact of clinical evidence communications and drug regulation changes concerning rosiglitazone on prescribing patterns of antidiabetic therapies.Adherence with renal dosing recommendations in outpatients undergoing haemodialysis.Ejaculatory responses are inhibited by a new chemical entity, DA-8031, in preclinical rodent models of ejaculation.Polymorphism in CYP2C9 as a non-critical factor of warfarin dosage adjustment in Korean patients.Onset time of hyperkalaemia after angiotensin receptor blocker initiation: when should we start serum potassium monitoring?Effects of cilostazol and renin-angiotensin system (RAS) blockers on the renal disease progression of Korean patients: a retrospective cohort study.Awareness and attitude of the public toward personalized medicine in Korea.Epidemiology of drug hypersensitivity reactions using 6-year national health insurance claim data from KoreaComparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in KoreaDurability of initial antidiabetic monotherapy and subsequent treatment adjustment patterns among newly treated type 2 diabetes patientsCYP2C19 polymorphism in Korean patients on warfarin therapyImpact of Statin Use on Dementia Incidence in Elderly Men and Women with Ischemic Heart DiseaseEffects of Statin Therapy on the Risk of Intracerebral Hemorrhage in Korean Patients with HyperlipidemiaARB Superiority Over ACE Inhibitors in Coronary Heart Disease: An Alternative ViewpointEfficacy of Aspirin in the Primary Prevention of Cardiovascular Diseases and Cancer in the Elderly: A Population-Based Cohort Study in KoreaEffects of sarpogrelate on microvascular complications with type 2 diabetes
P50
Q27006968-BCD5189B-EB7B-45BB-86C2-26C43BEBCB96Q28550517-72B496D3-16B3-4FB3-A8D3-AACF5B1C23C3Q30851245-6C1F1843-96AB-4EF4-9E2F-B6CAEB5782CAQ35453613-C127011A-CBD4-47FA-9270-CD07329C8A57Q37344471-DE047DDD-D294-4017-A75A-6B048B5B1BE7Q37872248-E60C3860-5E19-4425-A7E4-8155D58AB5D5Q38535640-3F4B52DB-EC13-46DF-8BFC-A4AFDDF4933BQ38573995-1250CA3D-7EF5-4F14-B4B0-BE9418CA232DQ38644070-66DCCF49-558F-4AC9-BE02-1774D9A7CC6DQ38672320-CFE855F9-1FCB-4E22-B371-D6580C690B69Q43495862-007E3693-68D3-404B-91AB-E2D1DF1531EDQ44684243-CD01E7DA-0735-4340-8AE8-0800C47F48DFQ44756155-1CAE608E-AB11-4981-ABCA-E70ABD84F702Q47761508-E8EC9AF8-FF2A-42CE-A967-BDC6F6A260E7Q49924790-D251F2D8-8625-4042-A928-46CFD2349E73Q56891333-4E175DA0-9321-4524-834A-8EE2866320B9Q57212904-224AF8B7-28D5-4660-9C1B-4A80AFCDEDF0Q58767163-AD1F7933-CD3D-40AC-8808-C2AFB0647F06Q80137530-BF035D1B-5CFD-4571-A81E-FDFC80506367Q89682298-D8754BFC-B5F9-4B5E-9593-938A1C6A7FD3Q90753472-A8757068-4513-46BE-9AA4-D43E5C2C26D9Q91000324-4F11D81F-94C2-46F1-BC1F-80F8D49D9FB0Q91390384-6DE4418B-725F-4C4D-A514-1897DBE588A1Q92318793-A7C0A9F8-98E4-453A-BB3D-E93A4D304F85
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sukhyang Lee
@ast
Sukhyang Lee
@en
Sukhyang Lee
@es
Sukhyang Lee
@nl
type
label
Sukhyang Lee
@ast
Sukhyang Lee
@en
Sukhyang Lee
@es
Sukhyang Lee
@nl
prefLabel
Sukhyang Lee
@ast
Sukhyang Lee
@en
Sukhyang Lee
@es
Sukhyang Lee
@nl
P106
P1153
42861816500
P31
P496
0000-0002-8830-4353